1,2-Bis(sulfonyl)hydrazines. 3. Effects of Structural Modification on Antineoplastic Activity

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 1987 Nov 1

PMID 3669023

Citations 7

Authors

K Shyam

R T Hrubiec

R Furubayashi

L A Cosby

A C Sartorelli

Affiliations

Soon will be listed here.

Abstract

A series of 1,2-bis(sulfonyl)hydrazines was synthesized and evaluated for antineoplastic activity against the L1210 leukemia and the B16 melanoma. The most active agent to emerge from this study, 1,2-bis(methylsulfonyl)-1-methylhydrazine, produced a maximum % T/C for mice bearing the L1210 leukemia or the B16 melanoma of 340% and 278%, respectively. Two N-chloroethyl analogues, conceived as bifunctional alkylating agents, were also synthesized and evaluated for antineoplastic activity against the L1210 leukemia and the B16 melanoma. Although such a modification resulted in retention of antineoplastic activity against both tumor cell lines, it did not result in enhanced antineoplastic activity.

Citing Articles

Anti-trypanosomal activity of nigerian plants and their constituents.

Nwodo N, Ibezim A, Ntie-Kang F, Adikwu M, Mbah C Molecules. 2015; 20(5):7750-71.

PMID: 25927903 PMC: 6272792. DOI: 10.3390/molecules20057750.

In vitro evaluation of 3-arylcoumarin derivatives in A549 cell line.

Musa M, Joseph M, Latinwo L, Badisa V, Cooperwood J Anticancer Res. 2015; 35(2):653-9.

PMID: 25667442 PMC: 4765731.

Influence of glutathione and glutathione S-transferases on DNA interstrand cross-link formation by 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, the active anticancer moiety generated by laromustine.

Penketh P, Patridge E, Shyam K, Baumann R, Zhu R, Ishiguro K Chem Res Toxicol. 2014; 27(8):1440-9.

PMID: 25012050 PMC: 4137992. DOI: 10.1021/tx500197t.

Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.

Ishiguro K, Zhu Y, Shyam K, Penketh P, Baumann R, Sartorelli A Biochem Pharmacol. 2010; 80(9):1317-25.

PMID: 20654586 PMC: 2950702. DOI: 10.1016/j.bcp.2010.07.022.

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.

Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E Invest New Drugs. 2005; 23(2):123-35.

PMID: 15744588 DOI: 10.1007/s10637-005-5857-6.